Loading company…
Guangzhou-based biopharmaceutical developer of next-generation probiotics and live biotherapeutics, founded in 2013.
Founded in 2013 and based in Guangzhou, China, Zhiyi Biotech develops next-generation probiotics and live biotherapeutics, and has more than 10 approved projects, including a National 863 Special Project. Its lead candidate SK08, based on a Bacteroides fragilis strain, was approved for clinical trials in November 2019, and a Phase II safety study enrolled in 2021. In April 2026 the company raised Series C+ funding from Jingyao Fund and Lehong Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in